Hanx Biopharmaceuticals’ HX009 Receives NMPA Clinical Trial Approval for PD-1/CD47 Bispecific Antibody
China-based Hanx Biopharmaceuticals Co., Ltd has announced that its self-developed anti PD-1/CD47 bispecific antibody drug,...
2019
LanssonPharm Secures Series A Funding to Accelerate CNS Drug Development
LanssonPharm, a company dedicated to the development of central nervous system (CNS) drugs, has announced...